Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 1/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | GRM8 | O00222 | 2/20 | 0.31 |
| ▸ | GRM6 | O15303 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738542 | 1.00 | SLC6A12 (0.38) | SLC6A12SLC6A11TSHRPOLBMEN1 | |
| SCHEMBL18204657 | 1.00 | SLC6A12 (0.38) | SLC6A12SLC6A11TSHRPOLBMEN1 | |
| SCHEMBL2996659 | 1.00 | SLC6A12 (0.38) | SLC6A12SLC6A11TSHRPOLBMEN1 | |
| SCHEMBL5507145 | 1.00 | SLC6A12 (0.38) | SLC6A12SLC6A11TSHRPOLBMEN1 | |
| SCHEMBL2996660 | 1.00 | SLC6A12 (0.38) | SLC6A12SLC6A11TSHRPOLBMEN1 | |
| SCHEMBL31721444 | 0.84 | EPHX1 (0.44) | SLC6A12SLC6A11MEN1KMT2AALDH1A1 | |
| SCHEMBL16617788 | 0.83 | SLC6A12 (0.41) | SLC6A12SLC6A11TSHRPOLBMEN1 | |
| SCHEMBL14780089 | 0.83 | GRM4 (0.33) | MEN1KMT2AALDH1A1GRM4CYP2C19 | |
| SCHEMBL14780275 | 0.83 | GRM4 (0.33) | MEN1KMT2AALDH1A1GRM4CYP2C19 | |
| SCHEMBL2988940 | 0.78 | CYP3A4 (0.38) | POLBALDH1A1LMNACYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184764-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7713979-B2 | Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1807072-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080275043-A1 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275043-A1 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSDL2, HSD17B1 | SLC6A12 3652/4885SLC6A11 2506/4885TSHR 4029/4885 |
| US-20100184764-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | SLC6A12 4133/4885SLC6A11 2623/4885TSHR 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.